LY 377604 is an innovative compound functioning as a mixed β3-adrenergic receptor agonist and β1/β2-adrenergic receptor antagonist, showing potential for antidiabetic and anti-obesity effects. In rodent models, LY 377604 has been found to enhance energy expenditure and fat oxidation, reduce blood glucose levels, and induce weight loss while preserving lean body mass. A phase II clinical trial for obesity has been conducted in the United States.